Benefits, Harms, and Costs
- 1The effects of estrogen deficiency on urogenital tissues include signs and symptoms of vulvovaginal atrophy, urinary urgency, dysuria, and recurrent urinary tract infection (high).
- 2Genitourinary syndrome of menopause is common and impairs quality of life, sexual function, and partner relationships (high).
- 3Without treatment, this syndrome will evolve chronically in most women and progress to functional and structural urogenital tissue changes that can be difficult to reverse even with treatment (high).
- 1Women entering menopause should be educated about the progressive impact of estrogen deficiency on urogenital health and the many options available for symptom relief (strong, high).
- 2Menopausal women should be comprehensively screened for genitourinary syndrome of menopause symptoms on an ongoing basis, as symptoms can present insidiously and become bothersome long after the menopausal transition (strong, high).
- 3First-line management options for genitourinary syndrome of menopause may include vaginal lubricants and/or vaginal moisturizers, particularly if patient concerns are limited to vaginal dryness or dyspareunia (strong, high).
- 4Second-line therapy for genitourinary syndrome of menopause is vaginal estrogen, administered either as a cream, tablet, or sustained-release ring (strong, high). Clinically significant systemic hormone absorption does not occur with low-dose therapy, so concomitant progestogen therapy is not needed (strong, high).
- 5Other second-line pharmacotherapy for atrophic vaginal symptoms includes the oral selective estrogen receptor modulator, ospemifene, and vaginal dehydroepiandrosterone ovules (strong, high).
- 6Long-term use of intravaginal laser therapy to manage genitourinary syndrome of menopause or stress urinary incontinence remains experimental and should be conducted only within the protocols of well-executed clinical trials designed to establish its safety and efficacy (strong, very low).
ABBREVIATIONS:CEE (conjugated equine estrogens), DHEA (dehydroepiandrosterone), GSM (genitourinary syndrome of menopause), UTI (urinary tract infection), DEFINITION (Genitourinary syndrome of menopause is a term recently adopted to comprehensively describe the effects of estrogen deficiency on the urogenital tissues. It includes the symptoms and signs of vulvovaginal atrophy, dyspareunia related to atrophy/dryness, overactive bladder, dysuria and recurrent urinary tract infections.)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Obstetrics and Gynaecology Canada
- The role of androgens in the treatment of genitourinary syndrome of menopause (gsm): International society for the study of women's sexual health (isswsh) expert consensus panel review.Menopause. 2018; 25: 837-847
- Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the international society for the study of women's sexual health and the north american menopause society.Climacteric. 2014; 17: 557-563
- The 2020 genitourinary syndrome of menopause position statement of the north american menopause society.Menopause. 2020; 27: 976-992
- Estrogen levels and estrogen receptors in patients with stress urinary incontinence and pelvic organ prolapse.Int J Gynaecol Obstet. 2003; 80: 35-39
- Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women.Sex Med. 2013; 1: 44-53
- Genitourinary syndrome of menopause.Clin Obstet Gynecol. 2018; 61: 508-516
- The burden of vulvovaginal atrophy on women's daily living: Implications on quality of life from a face-to-face real-life survey.Menopause. 2019; 26: 485-491
- The european vulvovaginal epidemiological survey (eves): Prevalence, symptoms and impact of vulvovaginal atrophy of menopause.Climacteric. 2018; 21: 286-291
- The closer (clarifying vaginal atrophy's impact on sex and relationships) survey: Implications of vaginal discomfort in postmenopausal women and in male partners.J Sex Med. 2013; 10: 2232-2241
- Urinary tract infection in postmenopausal women.Korean J Urol. 2011; 52: 801-808
- Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones.JAMA. 1983; 249: 2195-2198
- Cigarette smoking and age of menopause: A large prospective study.Maturitas. 2012; 72: 346-352
- Emas position statement: Predictors of premature and early natural menopause.Maturitas. 2019; 123: 82-88
- Impact of surgically induced weight loss on pelvic floor disorders.Int Urogynecol J. 2012; 23: 1111-1116
- Parabens and their effects on the endocrine system.Mol Cell Endocrinol. 2018; 474: 238-251
- Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition?.Climacteric. 2016; 19: 151-161
- Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: A randomized clinical trial.JAMA Intern Med. 2018; 178: 681-690
- Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: A single-arm feasibility study.Maturitas. 2019; 125: 57-62
- Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the hormones and urogenital therapy committee.Obstet Gynecol. 1998; 92: 722-727
- Sogc clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, may 2004.Int J Gynaecol Obstet. 2005; 88: 222-228
- Local oestrogen for vaginal atrophy in postmenopausal women.Cochrane Database Syst Rev. 2006; CD001500
- Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review.Female Pelvic Med Reconstr Surg. 2016; 22: 63-69
- Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection.J Infect Dis. 2001; 183: S74-S76
- A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.N Engl J Med. 1993; 329: 753-756
- A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (estring) on recurrent urinary tract infections in postmenopausal women.Am J Obstet Gynecol. 1999; 180: 1072-1079
- The rejoice trial: A phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.Menopause. 2017; 24: 409-416
- A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy.Br J Obstet Gynaecol. 1996; 103: 351-358
- Vaginal estrogen use and chronic disease risk in the nurses' health study.Menopause. 2018; 26: 603-610
- Endometrial safety of low-dose vaginal estrogens in menopausal women: A systematic evidence review.Menopause. 2019; 26 (Available at): 800-807
- Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study.Gynecol Endocrinol. 2010; 26: 404-412
- Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case-control study.Breast Cancer Res Treat. 2012; 135: 603-609
- Intracrinology.Mol Cell Endocrinol. 1991; 78: C113-C118
- Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).Menopause. 2015; 22: 950-963
- Efficacy of intravaginal dehydroepiandrosterone (dhea) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.Menopause. 2016; 23: 243-256
- Endometrial safety of ospemifene: Results of the phase 2/3 clinical development program.Menopause. 2015; 22: 36-43
- Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: Results of a randomized, placebo-controlled trial.Climacteric. 2015; 18: 226-232
- The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.Post Reprod Health. 2016; 22: 34-40
- 353-treatments for overactive bladder: Focus on pharmacotherapy - an addendum.J Obstet Gynaecol Can. 2017; 39: 1221-1229
- 283-treatments for overactive bladder: Focus on pharmacotherapy.J Obstet Gynaecol Can. 2018; 40: e22-e32
- Laser therapy for the restoration of vaginal function.Maturitas. 2017; 99: 10-15
- Use of a novel fractional co2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes.Menopause. 2017; 24: 810-814
- The use of laser in urogynaecology.Int Urogynecol J. 2019; 30: 683-692
- Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional co2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.Menopause. 2018; 25: 21-28
- A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The velvet trial.Menopause. 2020; 27: 50-56
- Long-term effect of thermoablative fractional co2 laser treatment as a novel approach to urinary incontinence management in women with genitourinary syndrome of menopause.Int Urogynecol J. 2018; 29: 211-215
- The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: A systematic review and meta-analysis.Clin Breast Cancer. 2019; 19: e556-ee62
- Lasers in the era of evidence-based medicine.Climacteric. 2020; 23: S6-S10
This document reflects emerging clinical and scientific advances as of the publication date and is subject to change. The information is not meant to dictate an exclusive course of treatment or procedure. Institutions are free to amend the recommendations. The SOGC suggests, however, that they adequately document any such amendments.
Informed consent: Everyone has the right and responsibility to make informed decisions about their care together with their health care providers. In order to facilitate this, the SOGC recommends that health care providers provide patients with information and support that is evidence-based, culturally appropriate, and personalized.
Language and inclusivity: The SOGC recognizes the importance to be fully inclusive and when context is appropriate, gender-neutral language will be used. In other circumstances, we continue to use gendered language because of our mission to advance women's health. The SOGC recognizes and respects the rights of all people for whom the information in this document may apply, including but not limited to transgender, non-binary, and intersex people. The SOGC encourages health care providers to engage in respectful conversation with their patients about their gender identity and preferred gender pronouns and to apply these guidelines in a way that is sensitive to each person's needs.